Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Emergent BioSolutions Inc Issues Q2 2013 Revenue Guidance In Line With Analysts' Estimates; Reaffirms FY 2013 Guidance


Thursday, 2 May 2013 04:01pm EDT 

Emergent BioSolutions Inc announced that for second quarter of 2013, it expects total revenues of $70 to $80 million. The Company reaffirmed fiscal 2013 guidance and expects total revenues of $290 to $310 million, split between product sales of $230 to $240 million and contracts and grants revenue of $60 to $70 million. The company is also reaffirming its fiscal 2013 net income forecast of $20 to $30 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $76 million for second quarter of 2013; revenue of $298 million and net income of $30 million for fiscal 2013. 

Company Quote

21.76
0.45 +2.11%
12:33pm EDT